A practical reference on preclinical models: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
== History == ITGA1 was first identified in 1986 as a Very Late Antigen-1 (VLA-1), a surface protein expressed on activated T lymphocytes. Later studies demonstrated that VLA-1 corresponds to the α1 integrin subunit, which pairs with the β1 integrin subunit to fom the α1β1 heterodimer, a receptor for collagen and laminin. During the early 1990s, cloning of the human ITGA1 gene enabled detailed characterization of its structure and tissue distribution. Structural studies later identified the α1 subunit as one of the integrins containing an inserted von Willebrand factor A domain responsible for collagen recognition. More recent research has expanded the biological significance of ITGA1 beyond cell adhesion to include roles in mechanotransduction, immune regulation, fibrosis, and cancer, leading to growing interest in ITGA1 as a potential therapeutic target.
==== Type 1 ==== Type 1 VWD (40-80% of all VWD cases) is a quantitative defect which is heterozygous for the defective gene. It arises from failure to secrete VWF into the circulation or, in the case of Type 1C, from VWF being cleared more quickly than normal. If VWF levels are greater than 50%, VWD can be ruled out. If VWF activity is below 30%, VWD is present. Patients with VWF activity between 0.30-0.50 IU/mL are classified based on their bleeding phenotype. If they have bleeding symptoms, they have VWD. If they have no bleeding, they are considered to have "Low VWF". Many patients are asymptomatic or may have mild symptoms and not have clearly impaired clotting, which might suggest a bleeding disorder. Often, the discovery of low VWF occurs incidentally to other medical procedures requiring a blood work-up. Most cases of low VWF are never diagnosed due to its asymptomatic or mild presentation, and most people with type I VWD end up leading a normal life free of complications, with many being unaware that they have the disorder. Trouble may, however, arise in some patients in the form of bleeding following surgery (including dental procedures), noticeable easy bruising, or menorrhagia (heavy menstrual periods). The minority of cases of type 1 may present with severe hemorrhagic symptoms.
However, in later versions both teams have gained substantial advantage from the addition of a map hotkey. This overlays the whole level, showing teammates and friendly structures; plus enemies and structures currently in view of comrades, and areas under attack. The aliens start with one active hive, randomly chosen from the 3 hive spots of the map. Active hives heal damaged aliens and respawn dead players. Marines initially spawn in a set location on the map, and after that spawn from Infantry Portals, which can be built in a set radius of the Command Chair. Healing and ammunition can be dropped by the commander in 'packs' (at a cost) or obtained free from an Armoury. The teams compete for territory, and critically for the resources ('res') it offers. The currency for both sides, resources are obtained by building resource towers to tap the nozzles sited around the map. This is another area where the teams have a key difference - while marines draw on a common pool of resources, each alien accumulates a personal store. This further increases the requirement for teamwork on the alien side, to achieve the right balance of hives, lifeforms, resource towers and chambers. The game ends when either all the marines or aliens are dead, and have no means to respawn. For the Frontiersmen (marine) side, this entails destroying all alien hives, ensuring no further alien players may respawn, and then hunting the rest down.
A lethal autonomous weapon is a machine that locates, selects and engages human targets without human supervision. Widely available AI tools can be used by bad actors to develop inexpensive autonomous weapons and, if produced at scale, they are potentially weapons of mass destruction. Even when used in conventional warfare, they currently cannot reliably choose targets and could potentially kill an innocent person. In 2014, 30 nations (including China) supported a ban on autonomous weapons under the United Nations' Convention on Certain Conventional Weapons, however the United States and others disagreed. By 2015, over fifty countries were reported to be researching battlefield robots.
(2026) study the isotopic composition of tooth enamel of ungulates from the three studied sites; the two studies provide evidence interpreted as indicative of persistence of Mediterranean seasonality and woodland ecosystems in the area of central Levantine coast between 400,000 and 100,000 years ago, resulting in existence of an ecological refugium that supporting diverse ungulate assemblages and enabled distinct, seasonal hominin foraging strategies, and evidence indicative of ecological differentiation between central and southern Levant in the studied time interval. Zeigen et al. (2026) study the isotopic composition of carbonate from the tooth enamel of the Persian fallow deers from sediments of the Amud Cave (Israel) associated with Neanderthal activity, interpreted as suggestive of exploitation of different habitats by fallow deer and gazelles from the site, and suggesting that fallow deer and gazelles were targeted by Neanderthals from the Amud Cave through different procurement strategies. Orbach et al. (2026) study the mammalian remains from a Pleistocene hyena den from the Geula Cave (Israel), reporting evidence of exploitation of similar ungulate communities by hyenas and humans during the mid-Middle Paleolithic, likely made possible by high ungulate diversity at the time, reducing competitive pressure between hyenas and humans. Hartman et al.
Sources: en.wikipedia.org
There are many types of treatment for the perichondral hematoma that can lead to cauliflower ear, but the current body of research is unable to identify a single best treatment or protocol. There is definitive evidence that the drainage of this hematoma is better for the prevention of cauliflower deformity when compared to conservative treatment, but the use of bandages and/or splinting after drainage requires more research. Because an acute hematoma can lead to cauliflower ear, prompt evacuation of the blood can prevent permanent deformity. There are many described techniques for the drainage of blood in the acute stage to prevent hematoma, including aspiration and drainage, incision and drainage, use of continuous suction devices and placing a wick. After the blood has been drained, the prevention of re-accumulation becomes the most pressing issue. This has been achieved with many techniques including: direct pressure dressings, in and out mattress sutures, buttons placed on sutures, thermoplastic splints, sutured cotton balls, and absorbable mattress sutures. The use of simple drainage becomes less useful after six hours from the injury and when there is recurrent trauma. In these cases it has been suggested that open surgical treatment is more effective in returning the cosmetic appearance and prevention of recurrence. The outer ear is prone to infections, so antibiotics are usually prescribed. Pressure can be applied by bandaging which helps the skin and the cartilage to reconnect.
== See also == Hydrogenosomes and mitosomes – mitochondrion-related organelles (MROs) Spinoloricus cinziae – an anaerobic microbial animal with hydrogenosome-like organelles Monocercomonoides – genus of eukaryotes that lack mitochondria and MROs entirely Anaerobic digestion Microbial fuel cell Standard electrode potential (data page) Table of standard reduction potentials for half-reactions important in biochemistry Lithotrophs
The controversy over the demolition of such a well-known landmark, and its deplored replacement, is often cited as a catalyst for the architectural preservation movement in the United States. Within the decade, Grand Central Terminal was protected under the city's new landmarks preservation act, a protection upheld by the courts in 1978 after a challenge by Grand Central's owner, Penn Central (the corporate successor of the PRR, following its merger with the rival New York Central Railroad).
=== Glutathione's impact on cellular balance, diseases, and drug development === Townsend's research has focused on the multifaceted role of glutathione and glutathione S-transferase (GST) in human disease, particularly their involvement in anti-cancer drug resistance, protein S-glutathionylation, and redox stress. She explored GSH's role in maintaining cellular balance, serving as a co-factor for enzymes, and influencing posttranslational modifications. This work emphasized GSH's crucial role in combating reactive oxygen species (ROS), implicated in diseases such as cancer, neurodegenerative diseases, cystic fibrosis (CF), HIV, and aging. Collaborating with Tew, she investigated the role of GSTs in the development of resistance to chemotherapy agents, proposing them as inhibitors of the MAP kinase pathway and potential therapeutic targets for various diseases, including neurodegenerative diseases, multiple sclerosis, and asthma. Her studies identified a role for GSTs as enzymatic mediators of S-glutathionylation of proteins. In her further research on cancer chemotherapy, she explored how cisplatin selectively kills proximal tubule cells, identified its metabolic pathway to a nephrotoxin, and showed that the metabolism in these cells is crucial for cisplatin-induced kidney damage, suggesting new targets for inhibition.
Antigen processing Apoptosis Biogenesis of organelles Cell cycle and division DNA transcription and repair Differentiation and development Immune response and inflammation Neural and muscular degeneration Maintenance of pluripotency Morphogenesis of neural networks Modulation of cell surface receptors, ion channels and the secretory pathway Response to stress and extracellular modulators Ribosome biogenesis Viral infection Phage defense
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.